Eligible patients with Relapsing-Remitting Multiple Sclerosis will be evaluated through a battery of validated cognitive function tests in MS, and through a retinal OCT scan of the eyes at baseline,12, and 24 months. Healthy age and sex matched participants will be invited to participate to obtain reference values of retinal layers’ thickness at baseline, 12 and 24 months.
- Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) at the AUBMC MS Center that were started on either interferon or fingolimod
- Healthy age and gender-matched participants
Non-probability sampling
- Subject able to attend yearly visits
- Patient diagnosed with RRMS according to 2005 McDonald's Criteria
- Patient with disease duration equal or less than 5 years
- Patient clinically stable not on any therapy, within 3-6 months of starting Gilenya, or more than 3 months after starting interferon
- Patient not currently experiencing optic neuritis
- Healthy subject with no history of demyelinating or neurodegenerative disorder
- Progressive MS or Neuromyelitis optica
- Diabetes Mellitus
- Glaucoma, refractive errors of +/- 6 diopters or more or other ophtalmologic disorders such as media opacities that may interfere with OCT measurements
- Systemic or CNS disorders that may interfere with cognitive testing